Related Experiment Video
Updated: Jan 24, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Treatment of K562 Cells with ABL Kinase Inhibitors Reveals Differential Metabolic Profiles
Pranay Renukuntla1,2, Sai Charitha Mullaguri3, Divya Presingu1,2
1Department of Analytical and Structural Chemistry, CSIR - Indian Institute of Chemical Technology, 500007, Hyderabad, India.
Abstract:
ABL kinase inhibitors have transformed the clinical management of chronic myelogenous leukemia; yet, the metabolic consequences of their use remain largely unexplored. In the current study, using K562 cell lines, the metabolic impact of five ABL kinase inhibitors, such as imatinib, dasatinib, nilotinib, ponatinib, and axitinib, was studied. Comparative metabolic profiling revealed both common and inhibitor-specific metabolic alterations. Pathway enrichment analysis identified significant downregulation in starch and sucrose metabolism, nucleotide sugar metabolism and sphingolipid metabolism. These results offered insights to guide the development of treatment strategies for overcoming the drug resistance in chronic myelogenous leukemia as well as managing the associated toxicities.
Insights
Five ABL kinase inhibitors impact chronic myelogenous leukemia (CML) cell metabolism. Researchers identified common and specific metabolic alterations, including downregulation in key metabolic pathways, offering insights for CML treatment strategies.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Tyrosine kinase inhibitors targeting ABL kinase have revolutionized chronic myelogenous leukemia (CML) treatment.
- The metabolic effects of these ABL kinase inhibitors are not well understood.
Purpose of the Study:
- To investigate the metabolic consequences of five ABL kinase inhibitors in K562 chronic myelogenous leukemia cells.
- To identify common and specific metabolic alterations induced by these drugs.
Main Methods:
- Utilized K562 cell lines for drug treatment.
- Performed comparative metabolic profiling.
- Conducted pathway enrichment analysis.
Main Results:
- Identified both shared and distinct metabolic changes across the five ABL kinase inhibitors.
- Observed significant downregulation in starch and sucrose metabolism.
- Noted downregulation in nucleotide sugar metabolism and sphingolipid metabolism.
Conclusions:
- The study reveals significant metabolic impacts of ABL kinase inhibitors in CML cells.
- Findings provide insights into managing drug resistance and toxicities associated with CML treatment.
- Metabolic profiling can guide the development of novel therapeutic strategies for chronic myelogenous leukemia.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
00:52What is Metabolism?
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...